We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Catalent has signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.